Maryland Oncology Hematology Launches In‑House Next Generation Sequencing Lab, Expanding Precision Cancer Care Access

Beltsville, MD — Maryland Oncology Hematology (MOH) has opened a new state‑of‑the‑art Next Generation Sequencing (NGS) laboratory, marking a significant step forward in making advanced genomic testing faster and more accessible for cancer patients throughout the region.

With this addition, MOH becomes one of the few private oncology practices in the United States to operate its own NGS facility—an advancement typically seen in large academic medical centers.

Bringing Genomic Testing Closer to Patients

NGS testing allows clinicians to examine hundreds of genes at once to detect mutations that drive cancer growth. These insights help oncologists determine which treatments may be most effective, including targeted therapies and clinical trials.

Traditionally, many community oncology practices must send patient samples to external laboratories, sometimes across the country. This can lead to wait times of two to three weeks before results are available. By establishing its own in‑house sequencing capabilities, MOH is positioned to provide results significantly faster.

“Having direct control over genomic testing means we can accelerate diagnoses and begin tailored treatment plans sooner,” says Maryland Oncology Hematology’s Dr. Kashif Firozvi. “For patients, that time matters.”

Improving Precision and Coordination

The new laboratory is designed specifically to support MOH’s precision medicine initiatives, offering physicians more immediate access to detailed molecular data. Lab specialists work directly with oncologists across the practice, ensuring a streamlined process for test selection, analysis, and interpretation.

The integration is expected to enhance both speed and accuracy in guiding treatment decisions—particularly for cancers where genetic mutations heavily influence therapy options.

A Rare Capability Among Community Cancer Centers

Only a small number of private oncology practices nationwide currently operate their own NGS facilities. MOH’s investment reflects a broader effort to bring advanced cancer technologies into community settings, allowing patients to receive high‑level diagnostic services without leaving their home region.

The organization’s leaders say the lab underscores its commitment to expanding access to precision medicine, reducing barriers to care, and maintaining high standards across its practice.

Supporting the Future of Cancer Care in Maryland

For patients, the new NGS lab represents faster answers, more personalized treatment options, and a more connected care experience. For clinicians, it provides a powerful resource that supports data‑driven decision‑making and keeps MOH at the forefront of oncology innovation.

The laboratory is now operational and ready to serve Maryland Oncology Hematology’s patients.